The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10447 malaria professionals are enjoying the free benefits of MalariaWorld today

glucose-6-phosphate dehydrogenase

Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis

May 19, 2020 - 14:28 -- Open Access
Author(s): 
Pfeffer DA, Ley B, Ric N. Price, et al.
Reference: 
PLoS Med 17(5): e1003084

The radical cure of Plasmodium vivax and P. ovale requires treatment with primaquine or tafenoquine to clear dormant liver stages. Either drug can induce haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, necessitating screening. The reference diagnostic method for G6PD activity is ultraviolet (UV) spectrophotometry; however, a universal G6PD activity threshold above which these drugs can be safely administered is not yet defined. Our study aimed to quantify assay-based variation in G6PD spectrophotometry and to explore the diagnostic implications of applying a universal threshold.

The prevalence of glucose-6-phosphate dehydrogenase deficiency in the Cape Verdean population in the context of malaria elimination

March 19, 2020 - 08:44 -- Open Access
Author(s): 
DePina AJ, Pires CM, Andrade AJB, Dia AK, Moreira AL, Ferreira MCM, Correia AJ, Faye O, Seck I, Niang EHA
Reference: 
PLoS One. 2020 Mar 16; 15(3):e0229574

Cabo Verde aims to eliminate malaria by 2020. In the country, Plasmodium falciparum had been the main parasite responsible for indigenous cases and primaquine is the first line treatment of cases and for radical cure. However, the lack of knowledge of the national prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency may be one of the constraints to the malaria elimination process. Hence, this first study determines the prevalence of G6PD deficiency (G6PDd) in the archipelago.

Corrigendum to: Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency

February 22, 2020 - 17:12 -- Open Access
Author(s): 
Taylor WRJ, Kheng S, Muth S, Tor P, Kim S, Bjorge S, Topps N, Kosal K, Sothea K, Souy P, Char CM, Vanna C, Ly P, Khieu V, Christophel E, Kerleguer A, Pantaleo A, Mukaka M, Menard D, Baird JK
Reference: 
The Journal of Infectious Diseases, Volume 221, Issue 5, 1 March 2020, Page 854

In “Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency” by Taylor et al [J Infect Dis 2019; 220(11): 1750–60], P values should be P < 0.001 where 0.000 is written. This has been updated in the article.

The authors regret these errors.

Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis

December 23, 2019 - 14:37 -- Open Access
Author(s): 
Ley B, Winasti Satyagraha A, Price RN, et al.
Reference: 
PLoS Med. 2019 Dec 13; 16(12):e1002992.

To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria. This systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from Access Bio/CareStart (Somerset, NJ) (CareStart Screening test for G6PD deficiency) for the diagnosis of G6PDd compared to the gold standard spectrophotometry (International Prospective Register of Systematic Reviews [PROSPERO]: CRD42019110994).

Subscribe to RSS - glucose-6-phosphate dehydrogenase